LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells

BMC Cancer

Susan MW Harrison²  Teresa Knifley¹  Min Chen³  Kathleen L O’Connor¹ 

[1] Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington 40506-0509, USA

[2] Markey Cancer Center, University of Kentucky, 741 S. Limestone Street, Lexington 40506-0509, USA

[3] Graduate Center for Toxicology, University of Kentucky, Lexington 40506-0509, USA

关键词: Invasion;    Chemotaxis;    Breast carcinoma;    MLCK;    MAPK;    Rac1;    ROCK;    RhoC;    RhoA;    Rho GTPases;   

Others  :  1079493
DOI  :  10.1186/1471-2407-13-501

 received in 2013-04-24, accepted in 2013-10-19,  发布年份 2013

【 摘 要 】

Background

Various pathways impinge on the actin-myosin pathway to facilitate cell migration and invasion including members of the Rho family of small GTPases and MAPK. However, the signaling components that are considered important for these processes vary substantially within the literature with certain pathways being favored. These distinctions in signaling pathways utilized are often attributed to differences in cell type or physiological conditions; however, these attributes have not been systematically assessed.

Methods

To address this question, we analyzed the migration and invasion of MDA-MB-231 breast carcinoma cell line in response to various stimuli including lysophosphatidic acid (LPA), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) and determined the involvement of select signaling pathways that impact myosin light chain phosphorylation.

Results

LPA, a potent stimulator of the Rho-ROCK pathway, surprisingly did not require the Rho-ROCK pathway to stimulate migration but instead utilized Rac and MAPK. In contrast, LPA-stimulated invasion required Rho, Rac, and MAPK. Of these three major pathways, EGF-stimulated MDA-MB-231 migration and invasion required Rho; however, Rac was essential only for invasion and MAPK was dispensable for migration. HGF signaling, interestingly, utilized the same pathways for migration and invasion, requiring Rho but not Rac signaling. Notably, the dependency of HGF-stimulated migration and invasion as well as EGF-stimulated invasion on MAPK was subject to the inhibitors used. As expected, myosin light chain kinase (MLCK), a convergence point for MAPK and Rho family GTPase signaling, was required for all six conditions.

Conclusions

These observations suggest that, while multiple signaling pathways contribute to cancer cell motility, not all pathways operate under all conditions. Thus, our study highlights the plasticity of cancer cells to adapt to multiple migratory cues.

【 授权许可】

   
2013 Harrison et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR: Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol 2009, 10:778-790.
• [2]Parsons JT, Horwitz AR, Schwartz MA: Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol 2010, 11(9):633-643.
• [3]Burridge K, Wennerberg K: Rho and Rac take center stage. Cell 2004, 116(2):167-179.
• [4]Spiering D, Hodgson L: Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh Migr 2011, 5(2):170-180.
• [5]Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci 2004, 117(20):4619-4628.
• [6]Kurokawa K, Matsuda M: Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Biol Cell 2005, 16(9):4294-4303.
• [7]Narumiya S, Tanji M, Ishizaki T: Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009, 28(1–2):65-76.
• [8]Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, et al.: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273(5272):245-248.
• [9]Sanders LC, Matsumura F, Bokoch GM, Lanerolle PD: Inhibition of myosin light chain kinase by p21-activated kinase. Science 1999, 283(5410):2083-2085.
• [10]Goeckeler ZM, Masaracchia RA, Zeng Q, Chew TL, Gallagher P, Wysolmerski RB: Phosphorylation of myosin light chain kinase by p21-activated kinase PAK2. J Biol Chem 2000, 275(24):18366-18374.
• [11]Delorme-Walker VD, Peterson JR, Chernoff J, Waterman CM, Danuser D, DerMardirossian C, Bokoch GM: Pak1 regulates focal adhesion strength, myosin IIA distribution, and actin dynamics to optimize cell migration. J Cell Biol 2011, 193(7):1289-1303.
• [12]Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K, Narumiya S: Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999, 285(5429):895-898.
• [13]Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999, 1(5):253-259.
• [14]Oser M, Condeelis J: The cofilin activity cycle in lamellipodia and invadopodia. J Cell Biochem 2009, 108(6):1252-1262.
• [15]Klemke M, Kramer E, Konstandin MH, Wabnitz GH, Samstag Y: An MEK-cofilin signalling module controls migration of human T cells in 3D but not 2D environments. EMBO J 2010, 29(17):2915-2929.
• [16]Klemke RL, Cai S, Giannini AL, Gallageher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated Protein kinase. J Cell Biol 1997, 137(2):481-492.
• [17]Wu D, Asiedu M, Wei Q: Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC. Oncogene 2009, 25(22):2219-2230.
• [18]Chen M, Towers LN, O’Connor KL: LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 2007, 292(5):C1927-C1933.
• [19]Trusolino L, Cavassa S, Angelini P, Andó M, Bertotti A, Comoglio PM, Boccaccio C: HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J 2000, 14(11):1629-1640.
• [20]Worthylake RA, Lemoine S, Watson JM, Burridge K: RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 2001, 154(1):147-160.
• [21]O’Connor KL, Chen M, Towers LN: Integrin α6β4 cooperates with LPA signaling to stimulate Rac through AKAP-Lbc-mediated RhoA activation. Am J Physiol Cell Physiol 2012, 302(3):C605-C614.
• [22]O’Connor KL, Nguyen B-K, Mercurio AM: RhoA function in lamellae formation and migration is regulated by the α6β4 integrin and cAMP. J Cell Biol 2000, 148(2):253-258.
• [23]O’Connor KL, Mercurio AM: Protein kinase A regulates Rac and is required for growth factor-stimulated migration of carcinoma cells. J Biol Chem 2001, 276(51):47895-47900.
• [24]Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y: Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004, 101(20):7618-7623.
• [25]Roussos ET, Condeelis JS, Patsialou A: Chemotaxis in cancer. Nat Rev Cancer 2011, 11(8):573-587.
• [26]Sigmundsdottir H, Butcher EC: Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008, 9(9):981-987.
• [27]Friedl P, Alexander S: Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147(5):992-1009.
• [28]Fukata Y, Oshiro N, Kinoshita N, Kawano Y, Matsuoka Y, Bennett V, Matsuura Y, Kaibuchi K: Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 1999, 145(2):347-361.
• [29]Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA: Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010, 70(12):5147-5154.
• [30]Chen M, Bresnick AR, O’Connor KL: Coupling S100A4 to Rhotekin alters Rho signaling output in breast cancer cells. Oncogene 2013, 32(32):3754-3764.
• [31]Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Dyk DEV, Pitts WJ, Earl RA, Hobbs F, et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998, 273(29):18623-18632.
• [32]Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270(46):27489-27494.
• [33]Dang ZC, Lowik CW: Differential effects of PD98059 and U0126 on osteogenesis and adipogenesis. J Cell Biochem 2004, 92(3):525-533.
• [34]Moolenaar WH, van Meeteren LA, Giepmans BNG: The ins and outs of lysophosphatidic acid signaling. Bioessays 2004, 26:870-881.